Raschi E.; Fusaroli M.; Massari F.; Mollica V.; Repaci A.; Ardizzoni A.; Poluzzi E.; Pagotto U.; Di Dalmazi G., The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System, «THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM», 2022, 107, pp. 3107 - 3114 [articolo]Open Access
De Giglio, Andrea; Tassinari, Elisa; Zappi, Arianna; Di Federico, Alessandro; Lenzi, Barbara; Sperandi, Francesca; Melotti, Barbara; Gelsomino, Francesco; Maltoni, Marco; Ardizzoni, Andrea, The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy, «CANCERS», 2022, 14, pp. 5845 - 5851 [articolo]Open Access
Nigro M.C.; Pirini M.G.; Garelli E.; Marchi M.; Musto A.; Pantaleo M.A.; Solli P.; Ardizzoni A.; Nannini M., Thoracic myopericytoma in an older adult, rare but possible: A case report, «THORACIC CANCER», 2022, 13, pp. 2532 - 2535 [articolo]Open Access
Di Federico A.; Filippini D.M.; Sperandi F.; Ardizzoni A.; Melotti B., Acute kidney injury as a possible immune-related adverse event associated with sustained complete response to BRAF and MEK inhibitors in advanced, V600E-mutated melanoma, «EUROPEAN JOURNAL OF CANCER», 2021, 147, pp. 58 - 59 [articolo]
Goss G.D.; Cobo M.; Lu S.; Syrigos K.; Lee K.H.; Goker E.; Georgoulias V.; Isla D.; Morabito A.; Min Y.J.; Ardizzoni A.; Bender S.; Cseh A.; Felip E., Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial, «ECLINICALMEDICINE», 2021, 37, Article number: 100940, pp. 1 - 9 [articolo]Open Access
Dall'Olio FG, Calabrò D, Conci N, Argalia G, Marchese PV, Fabbri F, Fragomeno B, Ricci D, Fanti S, Ambrosini V, Ardizzoni A., Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab., «EUROPEAN JOURNAL OF CANCER», 2021, 150, pp. 99 - 107 [articolo]
De Giglio A.; Scorsetti M.; Franceschini D.; Massari F.; Ardizzoni A., Bilateral radiation recall pneumonitis during immunotherapy for an advanced renal cell carcinoma: A challenging case enhances the need for a multidisciplinary approach, «EUROPEAN JOURNAL OF CANCER», 2021, 143, pp. 75 - 77 [articolo]
Filippini D.M.; Gatti M.; Di Martino V.; Cavalieri S.; Fusaroli M.; Ardizzoni A.; Raschi E.; Licitra L., Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis, «INTERNATIONAL JOURNAL OF CANCER», 2021, 149, pp. 675 - 683 [articolo]Open Access
Mollica, Veronica; Franceschini, Tania; Gruppioni, Elisa; Rizzo, Alessandro; Ricci, Costantino; Schiavina, Riccardo; Brunocilla, Eugenio; Ardizzoni, Andrea; Fiorentino, Michelangelo; Giunchi, Francesca; Massari, Francesco, Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing, «PATHOLOGY RESEARCH AND PRACTICE», 2021, 219, pp. 153350 - 153356 [articolo]
Mollica, Veronica; Franceschini, Tania; Gruppioni, Elisa; Rizzo, Alessandro; Ricci, Costantino; Schiavina, Riccardo; Brunocilla, Eugenio; Ardizzoni, Andrea; Fiorentino, Michelangelo; Giunchi, Francesca; Massari, Francesco, Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing, «PATHOLOGY RESEARCH AND PRACTICE», 2021, 219, Article number: 153350, pp. 1 - 7 [articolo]
Pantaleo M.A.; Mandruzzato M.; Indio V.; Urbini M.; Nannini M.; Gatto L.; Schipani A.; Fiorentino M.; Franceschini T.; Ambrosini V.; Di Scioscio V.; Saponara M.; Ianni M.; Concetti S.; Altimari A.; Ardizzoni A.; Astolfi A., Case Report: The Complete Remission of a Mixed Germ Cell Tumor With Somatic Type Malignancy of Sarcoma Type With a GCT-Oriented Therapy: Clinical Findings and Genomic Profiling, «FRONTIERS IN ONCOLOGY», 2021, 11, Article number: 633543, pp. 1 - 9 [articolo]Open Access
Rizzo A.; Mollica V.; Santoni M.; Rosellini M.; Marchetti A.; Ricci A.D.; Grilli G.; Greco A.; Montironi R.; Ardizzoni A.; Massari F., Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis, «IMMUNOTHERAPY», 2021, 13, pp. 783 - 793 [articolo]
Puglisi F.; Gerratana L.; Lambertini M.; Ceppi M.; Boni L.; Montemurro F.; Russo S.; Bighin C.; De Laurentiis M.; Giuliano M.; Bisagni G.; Durando A.; Turletti A.; Garrone O.; Ardizzoni A.; Gamucci T.; Colantuoni G.; Gravina A.; De Placido S.; Cognetti F.; Del Mastro L., Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer, «NPJ BREAST CANCER», 2021, 7, Article number: 82, pp. 1 - 9 [articolo]Open Access
Gelsomino F.; Tiseo M.; Barbieri F.; Riccardi F.; Cavanna L.; Frassoldati A.; Delmonte A.; Longo L.; Dazzi C.; Cinieri S.; Colantonio I.; Sperandi F.; Lamberti G.; Brocchi S.; Tofani L.; Boni L.; Ardizzoni A., Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) (British Journal of Cancer, (2020), 123, 1, (26-32), 10.1038/s41416-020-0845-3), «BRITISH JOURNAL OF CANCER», 2021, 125, pp. 306 - 306 [replica/breve intervento]
Raschi E.; Fusaroli M.; Ardizzoni A.; Poluzzi E.; De Ponti F., Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment, «BREAST CANCER RESEARCH AND TREATMENT», 2021, 186, pp. 219 - 227 [articolo]Open Access
